Page 12 - DIAGEN

Hermatology primeFISH Products

HEMATOLOGY

PANEL

17-043 PML-RARA t(15;17)

Translocations involving the PML (promyelocytic leukemia, are NPMl at 5q35, NUMAl at llql3, ZBTB16 (PLZF) at llq23,
also known as MYL) gene and the PARA (retinoic acid re- STAT5B at 17q21, PRKARlA at 17q24, FIPlll at 4ql2, and BCOR
ceptor alpha, RARa) gene are thought to be characteristic at Xpll. Because the PML/RARA fusion is responsible for
of acute promyelocyt ic leukemia (APL), a subtype of acute the response of these neoplasms to ali-trans retinoic acid
myeloid leukemia. The PML-RARA fusion gene is created (ATRA) therapy and other conven tional chemotherapy,
by the t(15;17)(q24;q21) translocation found in 90% of APL it is important to correctly distinguish between t(15;17)
cases, a leukemia that accounts for 5-8% of acute myeloid translocations and those involving other RARA partners.
leukemia (AML) cases. Variant RARA translocations may
be observed in a subset of cases. Known fusion partners

TRANSLOCATION

SHGC-144626 RH45099
5' 3'
Gen Tel
PML
589 kb NORMAL

15q24.1

D17S1215 RH12872
5' 3'
Gen Tel
17q12-q21.2 RARA TRANSLOCATION

685 kb

(Not to scale) TRANSLOCATION

www.diagen.com.tr References
Sanz MA, et al. (2009) Blood 113: 1875-91.
Kievits T, et al. (1990) Cytogenet Cell Genet 53: 134-6.
Swerdlow et al., (eds,) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, Lyon, France, 4th edition, IARC,2017
Zhang et al., Blood Reviews 2015;29(2):101-125
Tomita et al., International Journal of Haematology 2013;97(6):717-725

12 PRODUCT CATALOGUE info@diagen.com.tr